Axicabtagene ciloleucel is a type of CAR T-cell therapy that is used to recognize blood cancer cells and eliminated them. It is genetically modified T cells from the patient directed to CD19.
The drug is used in different types on non-Hodgkin lymphoma for adults with certain previous treatments, including large B-cell lymphoma and follicular lymphoma.